

Haematologica
HAEMATOL/2017/180505
Version 5

Pharmacological modulation of CXCR4 cooperates with BET
bromodomain inhibition in diffuse large B-cell lymphoma

Clara Recasens-Zorzo, Teresa Cardesa-Salzmann, Paolo Petazzi, Laia Ros-Blanco, Anna Esteve-Arenys, Guillem Clot, Martina Guerrero-Hernández, Vanina Rodríguez, Davide Soldini, Alexandra Valera, Alexandra Moros, Fina Climent, Eva González-Barca, Santiago Mercadal, Leonor Arenillas, Xavier Calvo, José Luís Mate, Gonzalo Gutiérrez-García, Isolda Casanova, Ramón Mangues, Alejandra Sanjuan-Pla, Clara Bueno, Pablo Menéndez, Antonio Martínez, Dolors Colomer, Roger Estrada-Tejedor, Jordi Teixidó, Elias Campo, Armando López-Guillermo, José Ignacio Borrell, Luis Colomo, Patricia Pérez-Galán, and Gaël Roué

Disclosures: The authors thank Ariadna Giro, Jocabed Roldan, Laura Jimenez and Sandra Cabezas (IDIBAPS) for expert technical assistance, and are grateful to Vera Uixo (IQS School of Engineering) for her help in docking study. We also thank Albert Martin Cirera for help in in vivo image processing. CPI203 was kindly provided by Constellation Pharmaceuticals (Cambridge, MA, USA). This work was supported by grants from Fondo de Investigacion Sanitaria PI12/01847 and PI15/00102 (to G.R.) and PI12/01536 (to A.L.-G.), European Regional Development Fund (ERDF, Una manera de hacer Europa), Integrated Excellence Grant from the Instituto de Salud Carlos III (ISCIII) PIE1313/00033 (to E.Ca. and P.P.-G.), Redes Tematicas de Investigacion Cooperativa de Cancer from the Instituto de Salud Carlos III (ISCIII) (RD12/0036/0004) (to D.C.) and RD12/0036/0039 (to E.Ca.), and Generalitat de Catalunya 2014SGR346 (to D.C.) and 2014SGR795 (to E.Ca.). A.E.-A. was recipient of a predoctoral fellowship from Ministerio de Educacion, Cultura y Deporte (FPU). This work was carried out, in part, at the Esther Koplowitz Center, Barcelona, under the CERCA Program (Generalitat de Catalunya).

Contributions: C.R.-Z. and T.C.-S. designed and performed experiments, analyzed and interpreted data, and wrote the manuscript; L.R.-B., R.E.-T., J.T. and J.I.B. provided essential compounds and performed docking studies. P.P., A.E.-A., M.G.-H., D.S., A.V., A.M. and C.B. performed experiments; G.C. performed statistical analysis. E.Co., F.C., E.G.-B., S.M., L.A., X.C., J.L.M. and G.G. helped in retrieving patient samples and clinical data; I.C. and R.M. helped in generating luciferase-expressing cells and in immunohistochemical studies; V.R., A.S.-P. and P.M. provided help with in vivo experiments; A.M., D.C., E.Ca., and A.L.-G. revised the manuscript; L.C., P.P.-G. and G.R. conceived the study, interpreted the data and wrote the manuscript. All authors read and approved the manuscript.